60 Degrees Pharmaceuticals (SXTP) Research & Development (2022 - 2026)
60 Degrees Pharmaceuticals' (SXTP) quarterly Research & Development came in at $598653.0 in Q2 2026, up 158.14% year-over-year from $231912.0 in Q2 2025, and up 112.69% quarter-over-quarter from $281464.0 in Q1 2026.
Powered by 
Analysis
60 Degrees Pharmaceuticals (SXTP) Research & Development (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Research & Development for 5 consecutive years, with $598653.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Research & Development rose 158.14% year-over-year to $598653.0 in Q2 2026; TTM through Jun 2026 was $2.3 million, a 7.98% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, down 57.76% from the prior year.
- Research & Development was $598653.0 for Q2 2026 at 60 Degrees Pharmaceuticals, up from $281464.0 in the prior quarter.
- Over five years, Research & Development peaked at $3.1 million in Q2 2024 and troughed at $48457.0 in Q4 2022.
- A 5-year average of $533664.4 and a median of $281464.0 in 2026 frame the typical range for Research & Development.
- Across the five-year window, Research & Development surged 1418.27% in 2024 and slumped 92.51% in 2025, its largest moves.
- Over 5 years, Research & Development stood at $48457.0 in 2022, then jumped by 106.78% to $100201.0 in 2023, then jumped by 512.72% to $613955.0 in 2024, then increased by 4.06% to $638873.0 in 2025, then dropped by 6.3% to $598653.0 in 2026.
- The last three Research & Development figures came in at $598653.0 (Q2 2026), $281464.0 (Q1 2026), and $638873.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.17 Bn | 38.51 Bn | 2.15 Bn | 970.00 Mn |
| 2 | Viatris | 18.99 Bn | 18.10 Bn | 1.46 Bn | 248.30 Mn |
| 3 | Dr Reddys Laboratories | 9.74 Bn | 9.56 Bn | 396.53 Mn | 60.90 Mn |
| 4 | Amneal Pharmaceuticals | 5.41 Bn | 5.29 Bn | 334.51 Mn | 39.02 Mn |
| 5 | Bausch Health Companies | 2.29 Bn | 451.38 Mn | 2.10 Bn | 173.00 Mn |
| 6 | Alvotech | 1.53 Bn | 1.39 Bn | 2.56 Mn | -21.86 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 14.75 Mn |
| 8 | Amphastar Pharmaceuticals | 1.03 Bn | 736.38 Mn | 93.47 Mn | 22.16 Mn |
| 9 | Fennec Pharmaceuticals | 393.29 Mn | 352.05 Mn | 17.15 Mn | 10.66 Mn |
| 10 | 60 Degrees Pharmaceuticals | 2.57 Mn | 1.55 Mn | 56,798.00 | 598,653.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 598,653.00 |
| Mar 31, 2026 | 281,464.00 |
| Dec 31, 2025 | 638,873.00 |
| Sep 30, 2025 | 809,777.00 |
| Jun 30, 2025 | 231,912.00 |
| Mar 31, 2025 | 370,813.00 |
| Dec 31, 2024 | 613,955.00 |
| Sep 30, 2024 | 940,063.00 |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 337,182.00 |
| Dec 31, 2023 | 100,201.00 |
| Sep 30, 2023 | 263,703.00 |
| Jun 30, 2023 | 203,872.00 |
| Mar 31, 2023 | 123,994.00 |
| Dec 31, 2022 | 48,457.00 |
| Sep 30, 2022 | 182,655.00 |
| Jun 30, 2022 | 231,394.00 |